View Future GrowthArterra Bioscience 過去の業績過去 基準チェック /56Arterra Bioscienceは、平均年間7%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間17.5% 0.9%収益成長率で 減少しています。 Arterra Bioscienceの自己資本利益率は15.9%であり、純利益率は33.5%です。主要情報6.99%収益成長率24.21%EPS成長率Biotechs 業界の成長14.79%収益成長率-0.85%株主資本利益率15.95%ネット・マージン33.50%前回の決算情報31 Dec 2025最近の業績更新分析記事 • May 10Arterra Bioscience's (BIT:ARBS) Promising Earnings May Rest On Soft FoundationsInvestors were disappointed with Arterra Bioscience S.p.A.'s ( BIT:ARBS ) earnings, despite the strong profit numbers...Reported Earnings • Oct 06First half 2024 earnings releasedFirst half 2024 results: Revenue: €2.56m (up 14% from 1H 2023). Net income: €517.3k (up 108% from 1H 2023). Profit margin: 20% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue.Reported Earnings • Jun 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €4.72m (down 1.8% from FY 2022). Net income: €1.08m (down 24% from FY 2022). Profit margin: 23% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses.Reported Earnings • Oct 05First half 2023 earnings releasedFirst half 2023 results: Revenue: €2.25m (down 10% from 1H 2022). Net income: €248.6k (down 63% from 1H 2022). Profit margin: 11% (down from 27% in 1H 2022). The decrease in margin was primarily driven by lower revenue.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €2.51m (up 14% from 1H 2021). Net income: €678.7k (up 74% from 1H 2021). Profit margin: 27% (up from 18% in 1H 2021).Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €4.74m (up 14% from FY 2020). Net income: €1.11m (flat on FY 2020). Profit margin: 23% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses.すべての更新を表示Recent updates分析記事 • May 10Arterra Bioscience's (BIT:ARBS) Promising Earnings May Rest On Soft FoundationsInvestors were disappointed with Arterra Bioscience S.p.A.'s ( BIT:ARBS ) earnings, despite the strong profit numbers...Upcoming Dividend • Apr 27Upcoming dividend of €0.15 per shareEligible shareholders must have bought the stock before 04 May 2026. Payment date: 06 May 2026. Trailing yield: 4.3%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (2.2%).New Risk • Apr 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Minor Risks Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.4m market cap, or US$23.9m).Declared Dividend • Mar 30Dividend increased to €0.15Dividend of €0.15 is 15% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 5.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 27% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Mar 28Arterra Bioscience S.p.A. announces Annual dividend, payable on May 06, 2026Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1500 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.分析記事 • Mar 28Here's Why We Think Arterra Bioscience (BIT:ARBS) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...お知らせ • Jan 21Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million.Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million on January 20, 2026. A cash consideration valued at €3.2 per share will be paid by Smart Capital S.p.A. Following the transaction, which took place outside the market, Smart Capital will hold 799,500 shares, thus increasing its stake from 5.00% to 12.01% of Arterra's share capital. Smart Capital S.p.A. (BIT:SMCAP) completed the acquisition of an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) on January 20, 2026.New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.8m market cap, or US$24.2m).Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €3.32, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total returns to shareholders of 114% over the past three years.New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (217% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€17.0m market cap, or US$19.8m).New Risk • May 22New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 289% Dividend yield: 5.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (289% cash payout ratio). Market cap is less than US$100m (€15.6m market cap, or US$17.6m).Upcoming Dividend • Apr 28Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Trailing yield: 5.5%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.9%).New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.6m revenue, or US$4.2m). Market cap is less than US$100m (€14.9m market cap, or US$17.0m).分析記事 • Apr 15Arterra Bioscience's (BIT:ARBS) Dividend Will Be Increased To €0.13The board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be paying its dividend of €0.13 on the...Buy Or Sell Opportunity • Apr 07Now 27% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €2.16. The fair value is estimated to be €1.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only.お知らせ • Apr 07Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025, at 11:00 W. Europe Standard Time. Location: via benedetto brin n 69 Italy分析記事 • Apr 01Arterra Bioscience (BIT:ARBS) Is Paying Out A Larger Dividend Than Last YearThe board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be increasing its dividend by 30% on the...Declared Dividend • Mar 31Dividend increased to €0.13Dividend of €0.13 is 30% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 6.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 26% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 31% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.お知らせ • Mar 30Arterra Bioscience S.p.A. announces Annual dividend, payable on May 07, 2025Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1300 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.Reported Earnings • Oct 06First half 2024 earnings releasedFirst half 2024 results: Revenue: €2.56m (up 14% from 1H 2023). Net income: €517.3k (up 108% from 1H 2023). Profit margin: 20% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue.Reported Earnings • Jun 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €4.72m (down 1.8% from FY 2022). Net income: €1.08m (down 24% from FY 2022). Profit margin: 23% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses.Upcoming Dividend • Apr 29Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Trailing yield: 5.2%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.8%).New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (€13.0m market cap, or US$13.8m).分析記事 • Feb 13Arterra Bioscience S.p.A.'s (BIT:ARBS) P/E Is On The MarkThere wouldn't be many who think Arterra Bioscience S.p.A.'s ( BIT:ARBS ) price-to-earnings (or "P/E") ratio of 12.6x...Reported Earnings • Oct 05First half 2023 earnings releasedFirst half 2023 results: Revenue: €2.25m (down 10% from 1H 2022). Net income: €248.6k (down 63% from 1H 2022). Profit margin: 11% (down from 27% in 1H 2022). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €1.64, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 44% over the past three years.Buying Opportunity • Sep 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be €2.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only.分析記事 • Aug 03A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ARBS)Key Insights The projected fair value for Arterra Bioscience is €1.90 based on 2 Stage Free Cash Flow to Equity Arterra...Upcoming Dividend • May 01Upcoming dividend of €0.10 per share at 4.0% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 4.0%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.4%).分析記事 • Jan 09A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ABS)Key Insights Arterra Bioscience's estimated fair value is €2.3 based on 2 Stage Free Cash Flow to Equity Current share...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Counselor Lucio Annunziato was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €2.51m (up 14% from 1H 2021). Net income: €678.7k (up 74% from 1H 2021). Profit margin: 27% (up from 18% in 1H 2021).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €4.74m (up 14% from FY 2020). Net income: €1.11m (flat on FY 2020). Profit margin: 23% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €2.00, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 33% over the past year.Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: €2.21m (up 40% from 1H 2020). Net income: €390.6k (up 13% from 1H 2020). Profit margin: 18% (down from 22% in 1H 2020). The decrease in margin was driven by higher expenses.Reported Earnings • Jun 13Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €4.17m (up 19% from FY 2019). Net income: €1.11m (up 29% from FY 2019). Profit margin: 27% (up from 24% in FY 2019). The increase in margin was driven by higher revenue.分析記事 • May 27Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)Today we will run through one way of estimating the intrinsic value of Arterra Bioscience S.p.A. ( BIT:ABS ) by taking...Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 23% share price gain to €4.08, the stock trades at a trailing P/E ratio of 46.8x. Average forward P/E is 35x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to €3.41, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 32.7x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total return to shareholders over the past year is a loss of 7.8%.Is New 90 Day High Low • Jan 08New 90-day high: €3.41The company is up 15% from its price of €2.96 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: €2.80The company is down 2.0% from its price of €2.87 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period.収支内訳Arterra Bioscience の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BIT:ARBS 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 25622031 Dec 24412030 Sep 24412030 Jun 24412031 Mar 24312031 Dec 23312030 Sep 23312030 Jun 23312031 Mar 23311031 Dec 22411030 Sep 22411030 Jun 22511031 Mar 22511031 Dec 21511030 Sep 21511030 Jun 21411031 Mar 21411031 Dec 20411030 Sep 20411030 Jun 20411031 Mar 20411031 Dec 19411030 Sep 19311030 Jun 19311031 Mar 19311031 Dec 18211031 Dec 172110質の高い収益: ARBSは 高品質の収益 を持っています。利益率の向上: ARBSの現在の純利益率 (33.5%)は、昨年(32%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ARBSの収益は過去 5 年間で年間7%増加しました。成長の加速: ARBSの過去 1 年間の収益成長率 ( 50.1% ) は、5 年間の平均 ( 年間7%を上回っています。収益対業界: ARBSの過去 1 年間の収益成長率 ( 50.1% ) はBiotechs業界50.1%を上回りました。株主資本利益率高いROE: ARBSの 自己資本利益率 ( 15.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 05:00終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Arterra Bioscience S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Valentina RomitelliValueTrack
分析記事 • May 10Arterra Bioscience's (BIT:ARBS) Promising Earnings May Rest On Soft FoundationsInvestors were disappointed with Arterra Bioscience S.p.A.'s ( BIT:ARBS ) earnings, despite the strong profit numbers...
Reported Earnings • Oct 06First half 2024 earnings releasedFirst half 2024 results: Revenue: €2.56m (up 14% from 1H 2023). Net income: €517.3k (up 108% from 1H 2023). Profit margin: 20% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue.
Reported Earnings • Jun 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €4.72m (down 1.8% from FY 2022). Net income: €1.08m (down 24% from FY 2022). Profit margin: 23% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses.
Reported Earnings • Oct 05First half 2023 earnings releasedFirst half 2023 results: Revenue: €2.25m (down 10% from 1H 2022). Net income: €248.6k (down 63% from 1H 2022). Profit margin: 11% (down from 27% in 1H 2022). The decrease in margin was primarily driven by lower revenue.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €2.51m (up 14% from 1H 2021). Net income: €678.7k (up 74% from 1H 2021). Profit margin: 27% (up from 18% in 1H 2021).
Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €4.74m (up 14% from FY 2020). Net income: €1.11m (flat on FY 2020). Profit margin: 23% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses.
分析記事 • May 10Arterra Bioscience's (BIT:ARBS) Promising Earnings May Rest On Soft FoundationsInvestors were disappointed with Arterra Bioscience S.p.A.'s ( BIT:ARBS ) earnings, despite the strong profit numbers...
Upcoming Dividend • Apr 27Upcoming dividend of €0.15 per shareEligible shareholders must have bought the stock before 04 May 2026. Payment date: 06 May 2026. Trailing yield: 4.3%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (2.2%).
New Risk • Apr 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Minor Risks Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.4m market cap, or US$23.9m).
Declared Dividend • Mar 30Dividend increased to €0.15Dividend of €0.15 is 15% higher than last year. Ex-date: 4th May 2026 Payment date: 6th May 2026 Dividend yield will be 5.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 27% per year over the past 4 years and payments have been stable during that time. Earnings per share has grown by 8.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 28Arterra Bioscience S.p.A. announces Annual dividend, payable on May 06, 2026Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1500 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
分析記事 • Mar 28Here's Why We Think Arterra Bioscience (BIT:ARBS) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
お知らせ • Jan 21Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million.Smart Capital S.p.A. (BIT:SMCAP) acquired an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) for €3.2 million on January 20, 2026. A cash consideration valued at €3.2 per share will be paid by Smart Capital S.p.A. Following the transaction, which took place outside the market, Smart Capital will hold 799,500 shares, thus increasing its stake from 5.00% to 12.01% of Arterra's share capital. Smart Capital S.p.A. (BIT:SMCAP) completed the acquisition of an additional 7.01% stake in Arterra Bioscience S.p.A. (BIT:ARBS) on January 20, 2026.
New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€20.8m market cap, or US$24.2m).
Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €3.32, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total returns to shareholders of 114% over the past three years.
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (217% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change). Revenue is less than US$5m (€4.2m revenue, or US$4.9m). Market cap is less than US$100m (€17.0m market cap, or US$19.8m).
New Risk • May 22New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 289% Dividend yield: 5.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (289% cash payout ratio). Market cap is less than US$100m (€15.6m market cap, or US$17.6m).
Upcoming Dividend • Apr 28Upcoming dividend of €0.13 per shareEligible shareholders must have bought the stock before 05 May 2025. Payment date: 07 May 2025. Trailing yield: 5.5%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.9%).
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.6m revenue, or US$4.2m). Market cap is less than US$100m (€14.9m market cap, or US$17.0m).
分析記事 • Apr 15Arterra Bioscience's (BIT:ARBS) Dividend Will Be Increased To €0.13The board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be paying its dividend of €0.13 on the...
Buy Or Sell Opportunity • Apr 07Now 27% overvalued after recent price riseOver the last 90 days, the stock has risen 4.9% to €2.16. The fair value is estimated to be €1.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
お知らせ • Apr 07Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025Arterra Bioscience S.p.A., Annual General Meeting, Apr 29, 2025, at 11:00 W. Europe Standard Time. Location: via benedetto brin n 69 Italy
分析記事 • Apr 01Arterra Bioscience (BIT:ARBS) Is Paying Out A Larger Dividend Than Last YearThe board of Arterra Bioscience S.p.A. ( BIT:ARBS ) has announced that it will be increasing its dividend by 30% on the...
Declared Dividend • Mar 31Dividend increased to €0.13Dividend of €0.13 is 30% higher than last year. Ex-date: 5th May 2025 Payment date: 7th May 2025 Dividend yield will be 6.0%, which is higher than the industry average of 2.8%. Sustainability & Growth The dividend has increased by an average of 26% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 31% to shift the payout ratio to a potentially unsustainable range, which is more than the 5.9% EPS decline seen over the last 5 years.
お知らせ • Mar 30Arterra Bioscience S.p.A. announces Annual dividend, payable on May 07, 2025Arterra Bioscience S.p.A. announced Annual dividend of EUR 0.1300 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
Reported Earnings • Oct 06First half 2024 earnings releasedFirst half 2024 results: Revenue: €2.56m (up 14% from 1H 2023). Net income: €517.3k (up 108% from 1H 2023). Profit margin: 20% (up from 11% in 1H 2023). The increase in margin was driven by higher revenue.
Reported Earnings • Jun 28Full year 2023 earnings releasedFull year 2023 results: Revenue: €4.72m (down 1.8% from FY 2022). Net income: €1.08m (down 24% from FY 2022). Profit margin: 23% (down from 29% in FY 2022). The decrease in margin was primarily driven by higher expenses.
Upcoming Dividend • Apr 29Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Trailing yield: 5.2%. Lower than top quartile of Italian dividend payers (5.7%). Higher than average of industry peers (1.8%).
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (€13.0m market cap, or US$13.8m).
分析記事 • Feb 13Arterra Bioscience S.p.A.'s (BIT:ARBS) P/E Is On The MarkThere wouldn't be many who think Arterra Bioscience S.p.A.'s ( BIT:ARBS ) price-to-earnings (or "P/E") ratio of 12.6x...
Reported Earnings • Oct 05First half 2023 earnings releasedFirst half 2023 results: Revenue: €2.25m (down 10% from 1H 2022). Net income: €248.6k (down 63% from 1H 2022). Profit margin: 11% (down from 27% in 1H 2022). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €1.64, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 44% over the past three years.
Buying Opportunity • Sep 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be €2.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
分析記事 • Aug 03A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ARBS)Key Insights The projected fair value for Arterra Bioscience is €1.90 based on 2 Stage Free Cash Flow to Equity Arterra...
Upcoming Dividend • May 01Upcoming dividend of €0.10 per share at 4.0% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Trailing yield: 4.0%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (2.4%).
分析記事 • Jan 09A Look At The Fair Value Of Arterra Bioscience S.p.A. (BIT:ABS)Key Insights Arterra Bioscience's estimated fair value is €2.3 based on 2 Stage Free Cash Flow to Equity Current share...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Counselor Lucio Annunziato was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021)First half 2022 results: EPS: €0 (in line with 1H 2021). Revenue: €2.51m (up 14% from 1H 2021). Net income: €678.7k (up 74% from 1H 2021). Profit margin: 27% (up from 18% in 1H 2021).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €4.74m (up 14% from FY 2020). Net income: €1.11m (flat on FY 2020). Profit margin: 23% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €2.00, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 33% over the past year.
Reported Earnings • Oct 03First half 2021 earnings releasedThe company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: €2.21m (up 40% from 1H 2020). Net income: €390.6k (up 13% from 1H 2020). Profit margin: 18% (down from 22% in 1H 2020). The decrease in margin was driven by higher expenses.
Reported Earnings • Jun 13Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €4.17m (up 19% from FY 2019). Net income: €1.11m (up 29% from FY 2019). Profit margin: 27% (up from 24% in FY 2019). The increase in margin was driven by higher revenue.
分析記事 • May 27Estimating The Intrinsic Value Of Arterra Bioscience S.p.A. (BIT:ABS)Today we will run through one way of estimating the intrinsic value of Arterra Bioscience S.p.A. ( BIT:ABS ) by taking...
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 23% share price gain to €4.08, the stock trades at a trailing P/E ratio of 46.8x. Average forward P/E is 35x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past year.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 20% share price gain to €3.41, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 32.7x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total return to shareholders over the past year is a loss of 7.8%.
Is New 90 Day High Low • Jan 08New 90-day high: €3.41The company is up 15% from its price of €2.96 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: €2.80The company is down 2.0% from its price of €2.87 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period.